The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by patients worldwide to treat a variety of diseases and serious medical conditions. PPTA member companies produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
PPTA works globally to:
PPTA Recognizes First Plasma Collection Centers Certified in Hungary +
ANNAPOLIS, MD—The Plasma Protein Therapeutics Association (PPTA) has awarded Plazmaferezis Állomás Kft (PFÁ), a member operating within the Kedrion group of companies, with International Quality Plasma Program (IQPP) certification for its plasma collection centers in Hungary; two in Budapest and one in Debrecen. The three centers are the first in the country to become IQPP certified.Read More
PPTA's Updated Response to Ontario's Proposal to Ban Compensated Plasma Donation +
The Plasma Protein Therapeutics Association (PPTA) remains deeply concerned about the proposal to ban compensated plasma donation in the Province of Ontario, Canada. The proposed legislation, Ontario Bill 178, unfairly targets compensated plasma donation on alleged bases of safety and Canada’s goal of self-sufficiency in regards to the supply of plasma-derived medicinal products.Read More
PPTA's Response to Ontario's Proposal to Ban Compensated Plasma Donation +
Members of the Plasma Protein Therapeutics Association (PPTA) are deeply concerned regarding the proposed legislation in the province of Ontario. It appears to have a goal of eliminating the possibility of compensating devoted donors for their time and inconvenience associated with a process called plasmapheresis, used to collect source plasma, the essential ingredient of life-saving plasma protein therapies.Read More
The Source, the international magazine of the plasma protein therapeutics industry is published quarterly.
Read the current issue.